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ABSTRACT-Intravesical BCG immunotherapy is commonly associated with 
irritative bladder symptoms. Bladder contracture as a result of this treatment is 
rare. Two cases of persistent small-capacity bladders occurring more than one 
year after intravesical BCG therapy are reported. 
Bacillus Calmette-Guerin (BCG) has docu- 
mented efficacy in the treatment of superficial 
bladder cancer.’ However, local toxicity with 
this agent tends to be greater than that found 
with other commonly employed intravesical 
chemotherapeutic agents, i.e., thiotepa, dox- 
orubicin, and mitomycin-C.2 In a review of 
1,278 patients, Lamm and associates3 reported 
that intravesical irritative symptoms (frequency 
and dysuria) were common and occurred in 
over 90 percent of the patients. Significant tox- 
icity was uncommon, and in only 2 patients a 
contracted bladder developed. Both of these pa- 
tients received the Tice strain on a monthly 
maintenance schedule without isoniazid pro- 
phylaxis. Of the five strains of BCG reviewed, 
the Connaught strain had the lowest incidence 
of complications. This report describes 2 pa- 
tients receiving intravesical BCG (Connaught 
strain) in whom long-term bladder contraction 
developed as a result of their therapy. 
Material and Methods 
From September 30,1983 through March 30, 
1988, 49 patients with superficial bladder can- 
cer were treated with intravesical BCG. Most of 
these patients were enrolled in one of several 
Southwest Oncology Group trials and were 
treated with Connaught strain BCG. The treat- 
ment course usually consisted of intravesical 
and percutaneous administration of 120 mg 
BCG weekly for six weeks. Some patients also 
received subsequent additional maintenance 
treatments with BCG. 
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Results 
In our group of patients irritative symptoms 
of frequency and dysuria following intravesical 
BCG were common. No patient suffered sys- 
temic toxicity. One patient had significant void- 
ing abnormalities with a small-capacity blad- 
der that resolved over a period of five months. 
Two patients have had contracted bladders that 
have persisted for over one year. Their clinical 
courses are described. 
Case 1 
A seventy-four-year-old woman began her 
BCG therapy in July 1986. She had a history of 
recurrent superficial bladder cancer dating 
back to 1982. Prior to starting BCG therapy, she 
had multiple transurethral resections of grade 
l-2 papillary transitional cell carcinomas. In 
addition, she had previously failed treatment 
with intravesical thiotepa, Adriamycin, and 
mitomycin-C, Her last intravesical chemother- 
apy treatment (with mitomycin-C) was in Jan- 
uary 1986. 
Cystoscopy on July 7, 1986 demonstrated 
another grade l-2, papillary transitional cell 
carcinoma. On July 14, 1986 she started a six- 
week course of Connaught BCG (intravesical 
and percutaneous). Despite gross hematuria, 
frequency, and urgency, she elected to complete 
her treatment course. One month later her 
symptoms persisted, and she was given iso- 
niazid 300 mg daily for thirty days. An ab- 
dominal film demonstrated bladder calcifica- 
tion (Fig. 1). In October, cystoscopy 
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FIGURE 1. Radiograph demonstrating calcifica- 
tion. 
demonstrated a grossly inflamed bladder with 
multiple areas of calcification of the bladder 
wall. Biopsy specimen demonstrated chronic 
inflammation. In June, several papillary grade 
2 transitional cell carcinomas were resected 
along with another tumor just inside the left 
ureteral orifice. Her bladder was small and 
chronically inflamed. In July and October 
1987, she had neodymium:yttrium-aluminum- 
garnet (Nd:YAG) laser therapy of the tumor in- 
side the left ureteral orifice. Since that time, 
ureteroscopic examination showed her ureter 
has been tumor free. She had another bladder 
tumor that had laser therapy in January 1988. 
At her last follow-up in April 1988, she had a 
70-mL capacity bladder with calculous cystitis 
on the posterior bladder wall (Fig. 2). The 
calculous material was easily removed with a 
biopsy forceps. Ureteroscopic examination 
demonstrated no tumor recurrence. Bladder 
biopsy specimen demonstrated chronic inflam- 
mation. 
Case 2 
A sixty-five-year-old woman started intraves- 
ical BCG in September 1986. She had a history 
of prior pelvic radiation and surgery in 1976 for 
carcinoma of the endometrium. Her first blad- 
der tumor was in 1984. She had several recur- 
rences (grade 2, noninvasive) and was started 
on a course of intravesical and percutaneous 
BCG on September 16, 1986. She received six 
weekly treatments with little toxicity. Follow- 
up cystoscopy and biopsy in December 1986 
demonstrated chronic granulomatous cystitis. 
On December 16, she began a maintenance 
schedule of three weekly treatments with BCG. 
After her last treatment, she had a flu-like syn- 
drome, mild urgency, and nocturia. 
Follow-up cystoscopy in March demon- 
strated bladder erythema with distention. On 
FIGURE 2. Endoscopic photograph demonstrating 
superficial bladder calcification. 
March 24, 1987, she began another main- 
tenance cycle of BCG. After her first dose, a 
mild flu-like syndrome developed along with 
urgency and frequency. After her second dose, a 
flu-like syndrome again developed. In addition, 
urgency and frequency were much worse and 
caused her to void hourly. She was not given her 
scheduled third treatment with BCG. In June 
1987, cystoscopy demonstrated diffuse inflam- 
mation with patchy areas of hemorrhage. Her 
bladder capacity was 50 mL. In September 
1987, cystoscopy demonstrated a bladder ca- 
pacity of 100 mL. Distention to this level 
caused diffuse bleeding. A biopsy specimen 
showed marked chronic inflammation. An ex- 
cretory urogram (IVP) demonstrated a small- 
capacity bladder. Follow-up cystoscopic ex- 
aminations in December 1987, March 1988, 
and June 1988 demonstrated no neoplasms. 
Bladder washings for cytologic examination 
were negative. Her bladder capacity had in- 
creased to 200 mL, but at that volume she had 
pain and diffuse hemorrhage. 
Comment 
Intravesical BCG has been remarkably effec- 
tive in preventing superficial bladder tumor re- 
currencel and progression to high-stage dis- 
ease.4 However, accompanying this therapeutic 
efficacy is a high incidence of minor to moder- 
ate local toxicity.3 Less commonly, more signifi- 
cant toxicities have occurred. These include 
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bladder outlet obstruction from granulomatous 
prostatitis,5 epididymitis,e granulomatous lym- 
phadenitis with ureteral obstruction,5 granu- 
lomatous hepatitis,e and tuberculous pneumo- 
nia.’ The incidence of each of these major 
complications is 0.3 percent or less.3 
The 2 patients with contracted bladders in 
this report attest to the fact that other strains of 
BCG besides Tice may cause this complication. 
Both of these patients had received previous 
therapy which may have contributed to their 
problems. Case 1 had failed therapy with 
multiple other intravesical chemotherapeutic 
agents and a calculous cystitis developed that 
ultimately resulted in bladder contracture. 
BCG does cause increased bacterial adherence 
and is associated with an increased incidence of 
urinary tract infections.8 This effect coupled 
with a heavily pretreated bladder may have re- 
sulted in this severe response. 
Case 2 had been treated with pelvic radiation 
ten years earlier. She tolerated an initial course 
of therapy with minimal morbidity. However, 
her second course of maintenance therapy 
caused severe symptoms resulting in stopping 
treatment after 2 instillations. The progressive 
increase in symptoms with subsequent treat- 
ments strongly suggests an immune basis for 
this phenomenon. A hypersensitivity phenome- 
non from intravesical BCG also has caused in- 
terstitial pneumonitis.g 
BCG remains an effective treatment modal- 
ity for superficial bladder cancer. However, it is 
important to be aware of the possibility of 
severe toxicity from this treatment. Individuals 
who have significant local symptoms should be 
monitored carefully. There is a small but signif- 
icant risk of long-term local morbidity and 
mortality from intravesical BCG im- 
munotherapy.‘O 
2916G Taubman Center 
Box 0330 
Ann Arbor, Michigan 48109 
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